RxDoctor Payments Data

Norman Abbott, MD

Cardiovascular Disease · Palm Harbor, FLNPI 1679582142

Payments from drug & device makers

$8,956in general payments, 2019–2025

Across 513 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Boehringer Ingelheim$602
  • Abbott$594
  • Actelion Pharmaceuticals US, Inc.$594
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$592
  • Johnson & Johnson$580
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$8,63796%
  • Education$3184%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,956 in reported general payments places this provider in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$333,781
Medicare patients
512
Services billed
4,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban341$300,397
XareltoRivaroxaban206$193,762
EntrestoSacubitril/Valsartan120$142,946
Repatha SureclickEvolocumab92$70,207
JardianceEmpagliflozin66$66,392
OzempicSemaglutide33$39,557
Dofetilide93$22,699
BrilintaTicagrelor22$17,120
Dabigatran EtexilateDabigatran Etexilate Mesylate53$16,345
Ranolazine ErRanolazine114$13,125
EdarbyclorAzilsartan Med/Chlorthalidone20$9,182
MyrbetriqMirabegron12$9,013
EdarbiAzilsartan Medoxomil20$6,197
Flecainide Acetate109$5,318
Metoprolol Succinate322$3,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$388$300,397341 claims
Johnson & JohnsonXarelto$580$193,762206 claims
NovartisEntresto$535$142,946120 claims
Boehringer IngelheimJardiance$602$66,39266 claims
Novo NordiskOzempic$358$39,55733 claims
AstraZenecaBrilinta$433$17,12022 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$36$15,38040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Palm Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →